162 results on '"Rasi G"'
Search Results
2. From adaptive licensing to adaptive pathways: Delivering a flexible life-span approach to bring new drugs to patients
3. Sovraconsumo di antibiotici ed eccesso di spesa farmaceutica
4. The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation
5. Methodology for development of the Allergic Rhinitis and its Impact on Asthma Guideline 2008 update
6. Predictive value of allergy and pulmonary function tests for the diagnosis of asthma in elite athletes
7. Nonspecific provocation of target organs in allergic diseases: EAACI-GA2LEN consensus report
8. Rhinitis and asthma in athletes: an ARIA document in collaboration with GA2LEN
9. Diagnosis of asthma and permitted use of inhaled β2-agonists in athletes
10. Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma
11. Nerve growth factor and asthma
12. Who benefits from immunotherapy?
13. Combination thymosin alpha sub 1 and lymphoblastoid interferon treatment in chronic hepatitis C
14. Combination low-dose lymphoblastoid interferon and thymosin α1 therapy in the treatment of chronic hepatitis B
15. AQUA: Allergy Questionnaire for Athletes. Development and validation.
16. Nonspecific provocation of target organs in allergic diseases: EAACI-GA2LEN consensus report.
17. Rhinitis and asthma in athletes: an ARIA document in collaboration with GA2LEN.
18. News and commentaries Diagnosis of asthma and permitted use of inhaled β2-agonists in athletes.
19. Combined treatment with thymosin-α1 and low dose interferon-α after dacarbazine in advanced melanoma.
20. PCN99 ITALIAN MONITORING REGISTRY OF BEVACIZUMAB IN THE TREATMENT OF METASTATIC COLON RECTAL CARCINOMA
21. Atopic and Vernal Keratoconjunctivitis: A Model for Studying Atopic Disease.
22. Combination low-dose lymphoblastoid interferon and thymosin α1 therapy in the treatment of chronic hepatitis B.
23. Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.
24. 524 POSTER Stimulatory effect of eucalyptus essential oil on macrophage/graulocyte phagocytic activity: in vitro and in vivo evidences
25. Lifestyle, Sports Activities and Allergic Diseases
26. Nerve Growth Factor Regulates the Production of Lung Mucins in a Transgenic Mice Model of Asthma
27. Epidemiological Study on Allergy and Asthma Phenotypes: Sub-clinical and Severe Asthma
28. Evaluation of antigen specific recognition and cell mediated cytotoxicity by a modified lysispot assay in a rat colon carcinoma model
29. Stimulatory effect of Eucalyptus essential oil on innate cell-mediated immune response
30. survivin-IgM immuno complex: A novel candidate biomarker of cirrhosis to monitor patients progression towards hepatocellular carcinoma.
31. AQUA©2007, an Allergy Questionnaire for Athletes.
32. Activation of human endogenous retrovirus-K and production of infectious viral-like particles in human melanoma cells.
33. Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: Clinical and immunological effects
34. Immunological changes induced by combined treatment with thymosin-alpha 1 and low-dose interferon-alpha after dacarbazine in advanced melanoma.
35. Combined treatment with thymosin-alpha 1 and low-dose interferon-alpha after dacarbazine in advanced melanoma.
36. Melanin, nucleotides, deoxynucleotides, and lipid peroxidation are modulated by TP-5 and oxidative stress in human melanoma cell lines in vitro.
37. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-αl and interferon-α2a
38. Treatment of solid tumors with combined Chemo-immunotherapy
39. 45 Atopy in twins
40. Human lens epithelial (HLE) cells in tissue culture: Differences and modification evaluated by fluss cytofluorimetric studies
41. Persistence of circulating CD169+monocytes and HLA-DR downregulation underline the immune response impairment in PASC individuals: the potential contribution of different COVID-19 pandemic waves.
42. Preliminary Evidence of the Differential Expression of Human Endogenous Retroviruses in Kawasaki Disease and SARS-CoV-2-Associated Multisystem Inflammatory Syndrome in Children.
43. Expression profile of HERVs and inflammatory mediators detected in nasal mucosa as a predictive biomarker of COVID-19 severity.
44. How CD4 + T Cells Transcriptional Profile Is Affected by Culture Conditions: Towards the Design of Optimal In Vitro HIV Reactivation Assays.
45. A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems.
46. High CD169 Monocyte/Lymphocyte Ratio Reflects Immunophenotype Disruption and Oxygen Need in COVID-19 Patients.
47. [Early access programs and managed entry agreements for medicines in Italy: results of a Focus Group (Early Access Programs and Managed Entry Agreement).]
48. Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements.
49. The COVID-19 crisis as an opportunity to strengthen global regulatory coordination for sustained enhanced access to diagnostics and therapeutics.
50. Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.